JP2017510555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510555A5 JP2017510555A5 JP2016551815A JP2016551815A JP2017510555A5 JP 2017510555 A5 JP2017510555 A5 JP 2017510555A5 JP 2016551815 A JP2016551815 A JP 2016551815A JP 2016551815 A JP2016551815 A JP 2016551815A JP 2017510555 A5 JP2017510555 A5 JP 2017510555A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- phenylcyclopropyl
- piperidin
- alkyl
- azetidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 97
- 150000003839 salts Chemical class 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 40
- 125000003118 aryl group Chemical group 0.000 claims 29
- 125000005843 halogen group Chemical group 0.000 claims 28
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 25
- 125000001424 substituent group Chemical group 0.000 claims 21
- 229910052799 carbon Inorganic materials 0.000 claims 17
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 16
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 13
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- -1 4-fluorophenylmethyl Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 8
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims 2
- LRISLSZFPGTNFP-CFYLOBDVSA-N 2-[1-(4-hydroxycyclohexanecarbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OC1CCC(CC1)C(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 LRISLSZFPGTNFP-CFYLOBDVSA-N 0.000 claims 2
- LNKLCUWGJGYEJN-YRTVTSRJSA-N 2-[1-(4-hydroxycyclohexyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OC1CCC(CC1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 LNKLCUWGJGYEJN-YRTVTSRJSA-N 0.000 claims 2
- WKZYPDVFDYESLQ-RBUKOAKNSA-N 2-[1-methylsulfonyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N WKZYPDVFDYESLQ-RBUKOAKNSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- VWIIMFORTMBPLN-UHFFFAOYSA-N 1-phenyl-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]cyclohexane-1-carbonitrile Chemical compound N#CC1(CCC(CC1)N1CC(CNC2CC2c2ccccc2)C1)c1ccccc1 VWIIMFORTMBPLN-UHFFFAOYSA-N 0.000 claims 1
- TVDKZBASXPLLBZ-FOIFJWKZSA-N 2-[1-(1-hydroxycyclopentanecarbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OC1(CCCC1)C(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 TVDKZBASXPLLBZ-FOIFJWKZSA-N 0.000 claims 1
- WNSIQTHQNNHKOU-GFOWMXPYSA-N 2-[1-(1-hydroxycyclopropanecarbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OC1(CC1)C(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 WNSIQTHQNNHKOU-GFOWMXPYSA-N 0.000 claims 1
- YSIRGVBHKRVSKU-FOIFJWKZSA-N 2-[1-(1-methylpyrazol-4-yl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound Cn1cc(cn1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 YSIRGVBHKRVSKU-FOIFJWKZSA-N 0.000 claims 1
- FTXZQOUPDXBLHA-FCHUYYIVSA-N 2-[1-(1-methylpyrazol-4-yl)sulfonyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1N=CC(=C1)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N FTXZQOUPDXBLHA-FCHUYYIVSA-N 0.000 claims 1
- BBEZPWPHOQIEGI-FCHUYYIVSA-N 2-[1-(1-methylpyrazole-4-carbonyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1N=CC(=C1)C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N BBEZPWPHOQIEGI-FCHUYYIVSA-N 0.000 claims 1
- XEDHJJBMYHJZND-UHFFFAOYSA-N 2-[1-(2-fluorobenzoyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound Fc1ccccc1C(=O)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 XEDHJJBMYHJZND-UHFFFAOYSA-N 0.000 claims 1
- YGKRJKSCOHXOOF-GFOWMXPYSA-N 2-[1-(2-hydroxyethyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OCCN1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 YGKRJKSCOHXOOF-GFOWMXPYSA-N 0.000 claims 1
- NQZHVXXBZTZCFM-LEWJYISDSA-N 2-[1-(2-methylpyrazole-3-carbonyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1N=CC=C1C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N NQZHVXXBZTZCFM-LEWJYISDSA-N 0.000 claims 1
- MJPVZDXQCTUQIG-UHFFFAOYSA-N 2-[1-(3,5-difluorobenzoyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound Fc1cc(F)cc(c1)C(=O)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 MJPVZDXQCTUQIG-UHFFFAOYSA-N 0.000 claims 1
- JHBCJWXVGNIDCD-UHFFFAOYSA-N 2-[1-(3-fluorobenzoyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound Fc1cccc(c1)C(=O)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 JHBCJWXVGNIDCD-UHFFFAOYSA-N 0.000 claims 1
- ZPVKWJUILDIPIU-BPGUCPLFSA-N 2-[1-(3-hydroxyazetidine-1-carbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OC1CN(C1)C(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 ZPVKWJUILDIPIU-BPGUCPLFSA-N 0.000 claims 1
- PPOYSOLYFOBOFP-YMOXTTMHSA-N 2-[1-(3-hydroxycyclobutyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OC1CC(C1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 PPOYSOLYFOBOFP-YMOXTTMHSA-N 0.000 claims 1
- QEODSRKCBHJXGW-UHFFFAOYSA-N 2-[1-(4-fluorobenzoyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound Fc1ccc(cc1)C(=O)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 QEODSRKCBHJXGW-UHFFFAOYSA-N 0.000 claims 1
- BSGNTEOUVKIDEX-UHFFFAOYSA-N 2-[1-(4-fluorobenzoyl)-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]piperidin-4-yl]acetonitrile Chemical compound Fc1ccc(cc1)C(=O)N1CCC(CC#N)(CC1)N1CC(CNC2CC2c2ccccc2)C1 BSGNTEOUVKIDEX-UHFFFAOYSA-N 0.000 claims 1
- CFEZGDDEXODSOP-OZAIVSQSSA-N 2-[1-(4-hydroxypiperidine-1-carbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound OC1CCN(CC1)C(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 CFEZGDDEXODSOP-OZAIVSQSSA-N 0.000 claims 1
- JDOVUIRQPWAANN-XMMISQBUSA-N 2-[1-(4-methoxypiperidine-1-carbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound COC1CCN(CC1)C(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 JDOVUIRQPWAANN-XMMISQBUSA-N 0.000 claims 1
- MOKIPZSEHIRCHU-UHFFFAOYSA-N 2-[1-(benzenesulfonyl)-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]piperidin-4-yl]acetonitrile Chemical compound O=S(=O)(N1CCC(CC#N)(CC1)N1CC(CNC2CC2c2ccccc2)C1)c1ccccc1 MOKIPZSEHIRCHU-UHFFFAOYSA-N 0.000 claims 1
- KQQSUVAYFVDCOX-XZOQPEGZSA-N 2-[1-(cyclopropylmethyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]-N,N-dimethylacetamide Chemical compound C1(CC1)CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)N(C)C KQQSUVAYFVDCOX-XZOQPEGZSA-N 0.000 claims 1
- POXDXBWDCJXXQK-FCHUYYIVSA-N 2-[1-(cyclopropylmethyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]-N-methylacetamide Chemical compound C1(CC1)CN1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)NC POXDXBWDCJXXQK-FCHUYYIVSA-N 0.000 claims 1
- GOBGZDUAYFOHAB-FOIFJWKZSA-N 2-[1-(morpholine-4-carbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)N1CCOCC1 GOBGZDUAYFOHAB-FOIFJWKZSA-N 0.000 claims 1
- SRPFBOAHKKBKKR-OZAIVSQSSA-N 2-[1-(oxan-4-yl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound N#CCC1(CN(C1)C1CCOCC1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 SRPFBOAHKKBKKR-OZAIVSQSSA-N 0.000 claims 1
- FXFHNEHARADBNL-JTGIGXABSA-N 2-[1-(oxolan-3-yl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1COCC1)CC#N FXFHNEHARADBNL-JTGIGXABSA-N 0.000 claims 1
- BMNSVVYABBFIOM-ATKRNPRHSA-N 2-[1-(oxolane-2-carbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C(C1CCCO1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 BMNSVVYABBFIOM-ATKRNPRHSA-N 0.000 claims 1
- PNLVAMICRIAANP-KITAHSCOSA-N 2-[1-(oxolane-3-carbonyl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C(C1CCOC1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 PNLVAMICRIAANP-KITAHSCOSA-N 0.000 claims 1
- BMNSVVYABBFIOM-HRUVVLKGSA-N 2-[1-[(2R)-oxolane-2-carbonyl]-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C([C@H]1CCCO1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 BMNSVVYABBFIOM-HRUVVLKGSA-N 0.000 claims 1
- BMNSVVYABBFIOM-PDQYLBCOSA-N 2-[1-[(2S)-oxolane-2-carbonyl]-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C([C@@H]1CCCO1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 BMNSVVYABBFIOM-PDQYLBCOSA-N 0.000 claims 1
- PNLVAMICRIAANP-PSQUCKQXSA-N 2-[1-[(3R)-oxolane-3-carbonyl]-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C([C@@H]1CCOC1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 PNLVAMICRIAANP-PSQUCKQXSA-N 0.000 claims 1
- PNLVAMICRIAANP-KFEBLCFASA-N 2-[1-[(3S)-oxolane-3-carbonyl]-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C([C@H]1CCOC1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 PNLVAMICRIAANP-KFEBLCFASA-N 0.000 claims 1
- NYIWGYPPKJPGTJ-GFOWMXPYSA-N 2-[1-[4-(methoxymethyl)-4-[[[(1R)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]cyclobutyl]acetic acid Chemical compound COCC1(CN[C@@H]2CC2c2ccccc2)CCN(CC1)C1(CC(O)=O)CCC1 NYIWGYPPKJPGTJ-GFOWMXPYSA-N 0.000 claims 1
- GHEGXJMODHODMQ-UHFFFAOYSA-N 2-[1-[4-[(2-phenylcyclopropyl)amino]piperidin-1-yl]cyclobutyl]acetonitrile Chemical compound N#CCC1(CCC1)N1CCC(CC1)NC1CC1c1ccccc1 GHEGXJMODHODMQ-UHFFFAOYSA-N 0.000 claims 1
- INRMDSMOHQTQSG-WUBHUQEYSA-N 2-[1-[4-[(4-fluorophenyl)methyl]-4-[[[(1R)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]cyclobutyl]acetic acid Chemical compound OC(=O)CC1(CCC1)N1CCC(CN[C@@H]2CC2c2ccccc2)(Cc2ccc(F)cc2)CC1 INRMDSMOHQTQSG-WUBHUQEYSA-N 0.000 claims 1
- RRYIYTAJBSSOPL-UHFFFAOYSA-N 2-[1-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]cyclobutyl]acetonitrile Chemical compound N#CCC1(CCC1)N1CCC(CNC2CC2c2ccccc2)CC1 RRYIYTAJBSSOPL-UHFFFAOYSA-N 0.000 claims 1
- ATMPNNXKBAQDJV-MUMRKEEXSA-N 2-[1-[4-[[[(1R)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]cyclobutyl]acetic acid Chemical compound OC(=O)CC1(CCC1)N1CCC(CN[C@@H]2CC2c2ccccc2)CC1 ATMPNNXKBAQDJV-MUMRKEEXSA-N 0.000 claims 1
- ZQLIYVSBBTXGFL-RBUKOAKNSA-N 2-[1-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]cyclobutyl]acetic acid Chemical compound CC1(CCN(CC1)C1(CCC1)CC(=O)O)CN[C@H]1[C@@H](C1)C1=CC=CC=C1 ZQLIYVSBBTXGFL-RBUKOAKNSA-N 0.000 claims 1
- CHLWPXFUYDMJHJ-VQTJNVASSA-N 2-[1-acetyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound C(C)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N CHLWPXFUYDMJHJ-VQTJNVASSA-N 0.000 claims 1
- JIGFNRMEKAMQDW-LEWJYISDSA-N 2-[1-acetyl-4-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]piperidin-4-yl]acetonitrile Chemical compound C(C)(=O)N1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N JIGFNRMEKAMQDW-LEWJYISDSA-N 0.000 claims 1
- QXXWMQDZVMZJOV-BJKOFHAPSA-N 2-[1-benzoyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound C(C1=CC=CC=C1)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N QXXWMQDZVMZJOV-BJKOFHAPSA-N 0.000 claims 1
- DYHJMPPSZFIVIQ-UHFFFAOYSA-N 2-[1-benzoyl-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1)c1ccccc1 DYHJMPPSZFIVIQ-UHFFFAOYSA-N 0.000 claims 1
- YIVORPSROJSZLH-LOSJGSFVSA-N 2-[1-benzyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound C(C1=CC=CC=C1)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N YIVORPSROJSZLH-LOSJGSFVSA-N 0.000 claims 1
- CBQUUHSDOMDECC-MUMRKEEXSA-N 2-[1-ethyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetic acid Chemical compound CCN1CC(CC(O)=O)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 CBQUUHSDOMDECC-MUMRKEEXSA-N 0.000 claims 1
- FHJDCJOIHQMOKO-GFOWMXPYSA-N 2-[1-ethylsulfonyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]-N-methylacetamide Chemical compound CCS(=O)(=O)N1CC(CC(=O)NC)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 FHJDCJOIHQMOKO-GFOWMXPYSA-N 0.000 claims 1
- UOUIRRWHFRPORZ-GFOWMXPYSA-N 2-[1-ethylsulfonyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 UOUIRRWHFRPORZ-GFOWMXPYSA-N 0.000 claims 1
- NKPUMNAEPKDNKZ-GFOWMXPYSA-N 2-[1-ethylsulfonyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]ethanol Chemical compound CCS(=O)(=O)N1CC(CCO)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 NKPUMNAEPKDNKZ-GFOWMXPYSA-N 0.000 claims 1
- OSXJNKWWLVSYHK-LEWJYISDSA-N 2-[1-ethylsulfonyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]-N,N-dimethylacetamide Chemical compound C(C)S(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)N(C)C OSXJNKWWLVSYHK-LEWJYISDSA-N 0.000 claims 1
- XZDHATBCLTUCFX-UHFFFAOYSA-N 2-[1-methyl-3-[4-[(2-phenylcyclopropyl)amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1CC(CC#N)(C1)N1CCC(CC1)NC1CC1c1ccccc1 XZDHATBCLTUCFX-UHFFFAOYSA-N 0.000 claims 1
- UUFGEUMETGJRQR-QRWMCTBCSA-N 2-[1-methyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetic acid Chemical compound CN1CC(CC(O)=O)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 UUFGEUMETGJRQR-QRWMCTBCSA-N 0.000 claims 1
- XZDHATBCLTUCFX-MUMRKEEXSA-N 2-[1-methyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 XZDHATBCLTUCFX-MUMRKEEXSA-N 0.000 claims 1
- LHGCYQPQMMRWBE-UHFFFAOYSA-N 2-[1-methyl-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound CN1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 LHGCYQPQMMRWBE-UHFFFAOYSA-N 0.000 claims 1
- FDRSPKPJWQDXPR-VQTJNVASSA-N 2-[1-methyl-4-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]piperidin-4-yl]acetonitrile Chemical compound CN1CCC(CC1)(N1CC(C1)CN[C@H]1[C@@H](C1)C1=CC=CC=C1)CC#N FDRSPKPJWQDXPR-VQTJNVASSA-N 0.000 claims 1
- NBGAAOKBUAFGJO-RBUKOAKNSA-N 2-[1-methylsulfonyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]ethanol Chemical compound CS(=O)(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CCO NBGAAOKBUAFGJO-RBUKOAKNSA-N 0.000 claims 1
- NCGLLDRHTVMYPJ-UHFFFAOYSA-N 2-[1-methylsulfonyl-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]piperidin-4-yl]acetonitrile Chemical compound CS(=O)(=O)N1CCC(CC#N)(CC1)N1CC(CNC2CC2c2ccccc2)C1 NCGLLDRHTVMYPJ-UHFFFAOYSA-N 0.000 claims 1
- WAOKAHCYIMPPGD-UHFFFAOYSA-N 2-[3-(cyanomethyl)-3-[4-[(2-phenylcyclopropyl)amino]piperidin-1-yl]azetidin-1-yl]benzonitrile Chemical compound N#CCC1(CN(C1)c1ccccc1C#N)N1CCC(CC1)NC1CC1c1ccccc1 WAOKAHCYIMPPGD-UHFFFAOYSA-N 0.000 claims 1
- JDCIQSZZZCQWTA-UHFFFAOYSA-N 2-[3-(cyanomethyl)-3-[4-[(2-phenylcyclopropyl)amino]piperidin-1-yl]azetidin-1-yl]pyridine-3-carbonitrile Chemical compound N#CCC1(CN(C1)c1ncccc1C#N)N1CCC(CC1)NC1CC1c1ccccc1 JDCIQSZZZCQWTA-UHFFFAOYSA-N 0.000 claims 1
- KLWGXIYQXBIWJD-VQTJNVASSA-N 2-[3-(cyanomethyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-1-yl]-N-methylacetamide Chemical compound C(#N)CC1(CN(C1)CC(=O)NC)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 KLWGXIYQXBIWJD-VQTJNVASSA-N 0.000 claims 1
- JXCHKGWNLZVMEZ-RBUKOAKNSA-N 2-[3-(cyanomethyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-1-yl]acetamide Chemical compound C(#N)CC1(CN(C1)CC(=O)N)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 JXCHKGWNLZVMEZ-RBUKOAKNSA-N 0.000 claims 1
- PWIOSBYHMSARTI-UHFFFAOYSA-N 2-[3-(cyanomethyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-1-yl]benzonitrile Chemical compound N#CCC1(CN(C1)c1ccccc1C#N)N1CCC(CNC2CC2c2ccccc2)CC1 PWIOSBYHMSARTI-UHFFFAOYSA-N 0.000 claims 1
- CTZRQHBOAPYTEO-UHFFFAOYSA-N 2-[3-(cyanomethyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-1-yl]pyridine-3-carbonitrile Chemical compound N#CCC1(CN(C1)c1ncccc1C#N)N1CCC(CNC2CC2c2ccccc2)CC1 CTZRQHBOAPYTEO-UHFFFAOYSA-N 0.000 claims 1
- UXIYDZIOOUEJGJ-DLBZAZTESA-N 2-[3-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CNC1)CC#N UXIYDZIOOUEJGJ-DLBZAZTESA-N 0.000 claims 1
- BWGRVHGXZYCISM-MUMRKEEXSA-N 2-[3-[4-[[(1R)-2-(4-fluorophenyl)cyclopropyl]amino]piperidin-1-yl]-1-methylsulfonylazetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccc(F)cc1 BWGRVHGXZYCISM-MUMRKEEXSA-N 0.000 claims 1
- IIDCSONIAIQNMY-GFOWMXPYSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1,2-thiazole-5-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)c1ccns1 IIDCSONIAIQNMY-GFOWMXPYSA-N 0.000 claims 1
- USUWNBOZHLVEAO-GFOWMXPYSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1,3-thiazol-2-ylmethyl)azetidin-3-yl]acetic acid Chemical compound OC(=O)CC1(CN(Cc2nccs2)C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 USUWNBOZHLVEAO-GFOWMXPYSA-N 0.000 claims 1
- GHWJMOSGGHRPOZ-BPGUCPLFSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1,3-thiazol-5-ylmethyl)azetidin-3-yl]acetic acid Chemical compound OC(=O)CC1(CN(Cc2cncs2)C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 GHWJMOSGGHRPOZ-BPGUCPLFSA-N 0.000 claims 1
- DEVUVKQKULAJNV-GFOWMXPYSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1,3-thiazole-2-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)c1nccs1 DEVUVKQKULAJNV-GFOWMXPYSA-N 0.000 claims 1
- UMLNPHYCWGBJOH-GFOWMXPYSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1,3-thiazole-4-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)c1cscn1 UMLNPHYCWGBJOH-GFOWMXPYSA-N 0.000 claims 1
- XGFPOLXECPYKPJ-GFOWMXPYSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1,3-thiazole-5-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)c1cncs1 XGFPOLXECPYKPJ-GFOWMXPYSA-N 0.000 claims 1
- TYHVLCMAEMDYCP-BPGUCPLFSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1H-pyrazole-4-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)c1cn[nH]c1 TYHVLCMAEMDYCP-BPGUCPLFSA-N 0.000 claims 1
- DAGXBMVVNPMYCV-VGAJERRHSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(1H-pyrazole-5-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)c1ccn[nH]1 DAGXBMVVNPMYCV-VGAJERRHSA-N 0.000 claims 1
- FMBNWGHWIFUXPF-XMMISQBUSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(2-pyridin-2-ylacetyl)azetidin-3-yl]acetonitrile Chemical compound O=C(Cc1ccccn1)N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 FMBNWGHWIFUXPF-XMMISQBUSA-N 0.000 claims 1
- WQPGXBJNMQFZEF-MUMRKEEXSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(3,3,3-trifluoropropyl)azetidin-3-yl]acetic acid Chemical compound OC(=O)CC1(CN(CCC(F)(F)F)C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 WQPGXBJNMQFZEF-MUMRKEEXSA-N 0.000 claims 1
- HGTYIFDNJSWEGV-BPGUCPLFSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(pyrazine-2-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(N1CC(CC#N)(C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1)c1cnccn1 HGTYIFDNJSWEGV-BPGUCPLFSA-N 0.000 claims 1
- PAODTXXDMLQHCY-BPGUCPLFSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(pyrimidin-2-ylmethyl)azetidin-3-yl]acetic acid Chemical compound OC(=O)CC1(CN(Cc2ncccn2)C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 PAODTXXDMLQHCY-BPGUCPLFSA-N 0.000 claims 1
- NLKWZDUQUSVPJL-FOIFJWKZSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]-1-(pyrimidin-5-ylmethyl)azetidin-3-yl]acetic acid Chemical compound OC(=O)CC1(CN(Cc2cncnc2)C1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 NLKWZDUQUSVPJL-FOIFJWKZSA-N 0.000 claims 1
- XVOKNSJVLHJVLS-QRWMCTBCSA-N 2-[3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound N#CCC1(CNC1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 XVOKNSJVLHJVLS-QRWMCTBCSA-N 0.000 claims 1
- MEHVWKKCGUIXNI-STTLMXHVSA-N 2-[3-[4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]piperidin-1-yl]-1-(4-hydroxycyclohexyl)azetidin-3-yl]acetonitrile Chemical compound FC1=CC=C(C=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CN(C1)C1CCC(CC1)O)CC#N MEHVWKKCGUIXNI-STTLMXHVSA-N 0.000 claims 1
- XVOKNSJVLHJVLS-ZWKOTPCHSA-N 2-[3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NC1CCN(CC1)C1(CNC1)CC#N XVOKNSJVLHJVLS-ZWKOTPCHSA-N 0.000 claims 1
- XVOKNSJVLHJVLS-MSOLQXFVSA-N 2-[3-[4-[[(1S,2R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1(=CC=CC=C1)[C@@H]1[C@H](C1)NC1CCN(CC1)C1(CNC1)CC#N XVOKNSJVLHJVLS-MSOLQXFVSA-N 0.000 claims 1
- TUXVOJPDNKEUES-UHFFFAOYSA-N 2-[3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]-1-[3-(trifluoromethyl)pyridin-2-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)c1cccnc1N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 TUXVOJPDNKEUES-UHFFFAOYSA-N 0.000 claims 1
- ITMDMKOHSAXUAX-UHFFFAOYSA-N 2-[3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]-1-[5-(trifluoromethyl)pyridin-2-yl]azetidin-3-yl]acetonitrile Chemical compound FC(F)(F)c1ccc(nc1)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 ITMDMKOHSAXUAX-UHFFFAOYSA-N 0.000 claims 1
- DOMHYKFZPPFFSW-UHFFFAOYSA-N 2-[3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetic acid Chemical compound OC(=O)CC1(CNC1)N1CCC(CNC2CC2c2ccccc2)CC1 DOMHYKFZPPFFSW-UHFFFAOYSA-N 0.000 claims 1
- SFXSOHVWLSFZFW-UHFFFAOYSA-N 2-[3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetonitrile Chemical compound N#CCC1(CNC1)N1CCC(CNC2CC2c2ccccc2)CC1 SFXSOHVWLSFZFW-UHFFFAOYSA-N 0.000 claims 1
- IADKUDSGXJARPU-RBUKOAKNSA-N 2-[4-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]azetidin-1-yl]piperidin-4-yl]acetonitrile Chemical compound C1(=CC=CC=C1)[C@H]1[C@@H](C1)NCC1CN(C1)C1(CCNCC1)CC#N IADKUDSGXJARPU-RBUKOAKNSA-N 0.000 claims 1
- VFHTVJZMYGMJST-UHFFFAOYSA-N 2-chloro-6-[3-(cyanomethyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-1-yl]benzonitrile Chemical compound Clc1cccc(N2CC(CC#N)(C2)N2CCC(CNC3CC3c3ccccc3)CC2)c1C#N VFHTVJZMYGMJST-UHFFFAOYSA-N 0.000 claims 1
- XOABJLMYTOAXDU-UHFFFAOYSA-N 2-phenyl-N-[[1-(1-phenylpiperidin-4-yl)azetidin-3-yl]methyl]cyclopropan-1-amine Chemical compound C(NC1CC1c1ccccc1)C1CN(C1)C1CCN(CC1)c1ccccc1 XOABJLMYTOAXDU-UHFFFAOYSA-N 0.000 claims 1
- GLXPUBZSNUMXBZ-ZWKOTPCHSA-N 3-(cyanomethyl)-3-[4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]piperidin-1-yl]azetidine-1-sulfonamide Chemical compound C(#N)CC1(CN(C1)S(=O)(=O)N)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=C(C=C1)F GLXPUBZSNUMXBZ-ZWKOTPCHSA-N 0.000 claims 1
- GMBKWWMGXRBRKT-ZWKOTPCHSA-N 3-(cyanomethyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-sulfonamide Chemical compound C(#N)CC1(CN(C1)S(=O)(=O)N)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 GMBKWWMGXRBRKT-ZWKOTPCHSA-N 0.000 claims 1
- AQLWLNLLRWETFZ-VQTJNVASSA-N 3-(cyanomethyl)-N,N-dimethyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-sulfonamide Chemical compound C(#N)CC1(CN(C1)S(=O)(=O)N(C)C)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 AQLWLNLLRWETFZ-VQTJNVASSA-N 0.000 claims 1
- QFHDHMBBBAWCFI-UHFFFAOYSA-N 3-(cyanomethyl)-N-(2,4-difluorophenyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidine-1-carboxamide Chemical compound Fc1ccc(NC(=O)N2CC(CC#N)(C2)N2CCC(CNC3CC3c3ccccc3)CC2)c(F)c1 QFHDHMBBBAWCFI-UHFFFAOYSA-N 0.000 claims 1
- VJCRHXYGKIEQEH-RBUKOAKNSA-N 3-(cyanomethyl)-N-methyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-sulfonamide Chemical compound C(#N)CC1(CN(C1)S(=O)(=O)NC)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 VJCRHXYGKIEQEH-RBUKOAKNSA-N 0.000 claims 1
- ZKXDFFPSTBNTFS-LEWJYISDSA-N 3-[2-(dimethylamino)-2-oxoethyl]-N,N-dimethyl-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-carboxamide Chemical compound CN(C(CC1(CN(C1)C(=O)N(C)C)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)=O)C ZKXDFFPSTBNTFS-LEWJYISDSA-N 0.000 claims 1
- RWNJNROHWPRAPM-VQTJNVASSA-N 3-[3-(cyanomethyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-1-yl]propanoic acid Chemical compound C(#N)CC1(CN(C1)CCC(=O)O)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 RWNJNROHWPRAPM-VQTJNVASSA-N 0.000 claims 1
- VUGJEBCUYKUMNE-UHFFFAOYSA-N 3-cyano-4-[3-(cyanomethyl)-3-[4-[(2-phenylcyclopropyl)amino]piperidin-1-yl]azetidin-1-yl]benzoic acid Chemical compound C(#N)C=1C=C(C(=O)O)C=CC=1N1CC(C1)(N1CCC(CC1)NC1C(C1)C1=CC=CC=C1)CC#N VUGJEBCUYKUMNE-UHFFFAOYSA-N 0.000 claims 1
- GZYXUPOSMJNNNG-UHFFFAOYSA-N 4-(cyanomethyl)-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]-N-propan-2-ylpiperidine-1-carboxamide Chemical compound CC(C)NC(=O)N1CCC(CC#N)(CC1)N1CC(CNC2CC2c2ccccc2)C1 GZYXUPOSMJNNNG-UHFFFAOYSA-N 0.000 claims 1
- NOQVNHUJKIVFEW-UHFFFAOYSA-N 4-(cyanomethyl)-N,N-dimethyl-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]piperidine-1-carboxamide Chemical compound CN(C)C(=O)N1CCC(CC#N)(CC1)N1CC(CNC2CC2c2ccccc2)C1 NOQVNHUJKIVFEW-UHFFFAOYSA-N 0.000 claims 1
- JPPOIZFRLNQZDJ-UHFFFAOYSA-N 4-(cyanomethyl)-N-(4-fluorophenyl)-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]piperidine-1-carboxamide Chemical compound Fc1ccc(NC(=O)N2CCC(CC#N)(CC2)N2CC(CNC3CC3c3ccccc3)C2)cc1 JPPOIZFRLNQZDJ-UHFFFAOYSA-N 0.000 claims 1
- CVXHLUSQNWCTAM-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-[(2-phenylcyclopropyl)amino]piperidin-1-yl]azetidin-1-yl]benzonitrile Chemical compound N#CCC1(CN(C1)c1ccc(cc1)C#N)N1CCC(CC1)NC1CC1c1ccccc1 CVXHLUSQNWCTAM-UHFFFAOYSA-N 0.000 claims 1
- SIOQWJTYOGOHDJ-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-1-yl]-2,5-difluoro-N-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)c1cc(F)c(cc1F)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 SIOQWJTYOGOHDJ-UHFFFAOYSA-N 0.000 claims 1
- LDQZIOZDTIHCGW-UHFFFAOYSA-N 4-[3-(cyanomethyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-1-yl]benzonitrile Chemical compound N#CCC1(CN(C1)c1ccc(cc1)C#N)N1CCC(CNC2CC2c2ccccc2)CC1 LDQZIOZDTIHCGW-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- JBMXDXFJXJLJSZ-XMMISQBUSA-N N,N-dimethyl-2-[1-(oxan-4-yl)-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetamide Chemical compound CN(C)C(=O)CC1(CN(C1)C1CCOCC1)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 JBMXDXFJXJLJSZ-XMMISQBUSA-N 0.000 claims 1
- LHQXFINMYQORHT-VQTJNVASSA-N N,N-dimethyl-2-[1-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]cyclobutyl]acetamide Chemical compound CN(C(CC1(CCC1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)=O)C LHQXFINMYQORHT-VQTJNVASSA-N 0.000 claims 1
- QMCGPOOLGHNHTJ-LEWJYISDSA-N N,N-dimethyl-2-[1-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]cyclobutyl]acetamide Chemical compound CN(C(CC1(CCC1)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)C)=O)C QMCGPOOLGHNHTJ-LEWJYISDSA-N 0.000 claims 1
- OINBUCHQWKHXGE-GFOWMXPYSA-N N,N-dimethyl-2-[1-methylsulfonyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetamide Chemical compound CN(C)C(=O)CC1(CN(C1)S(C)(=O)=O)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 OINBUCHQWKHXGE-GFOWMXPYSA-N 0.000 claims 1
- NNGVVKXEUSNXHF-VQTJNVASSA-N N,N-dimethyl-3-[2-(methylamino)-2-oxoethyl]-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-carboxamide Chemical compound CN(C(=O)N1CC(C1)(N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)CC(=O)NC)C NNGVVKXEUSNXHF-VQTJNVASSA-N 0.000 claims 1
- MNXLPLGILREJMI-UHFFFAOYSA-N N-(3-chloro-2-fluorophenyl)-3-(cyanomethyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidine-1-carboxamide Chemical compound Fc1c(Cl)cccc1NC(=O)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 MNXLPLGILREJMI-UHFFFAOYSA-N 0.000 claims 1
- NRMYICXRCKYDGH-RBUKOAKNSA-N N-methyl-2-[1-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]cyclobutyl]acetamide Chemical compound CNC(CC1(CCC1)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)=O NRMYICXRCKYDGH-RBUKOAKNSA-N 0.000 claims 1
- CALXIMFKIFKIMQ-VQTJNVASSA-N N-methyl-2-[1-[4-methyl-4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]piperidin-1-yl]cyclobutyl]acetamide Chemical compound CNC(CC1(CCC1)N1CCC(CC1)(CN[C@H]1[C@@H](C1)C1=CC=CC=C1)C)=O CALXIMFKIFKIMQ-VQTJNVASSA-N 0.000 claims 1
- NKLIIIQKMHWWRE-MUMRKEEXSA-N N-methyl-2-[1-methylsulfonyl-3-[4-[[(1R)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidin-3-yl]acetamide Chemical compound CNC(=O)CC1(CN(C1)S(C)(=O)=O)N1CCC(CC1)N[C@@H]1CC1c1ccccc1 NKLIIIQKMHWWRE-MUMRKEEXSA-N 0.000 claims 1
- CNQGUUGQPWCPFS-UHFFFAOYSA-N N-methyl-2-[3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidin-3-yl]acetamide Chemical compound CNC(=O)CC1(CNC1)N1CCC(CNC2CC2c2ccccc2)CC1 CNQGUUGQPWCPFS-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- JPTGAPQWKGYFGD-UHFFFAOYSA-N ethyl 4-(cyanomethyl)-4-[3-[[(2-phenylcyclopropyl)amino]methyl]azetidin-1-yl]piperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(CC#N)(CC1)N1CC(CNC2CC2c2ccccc2)C1 JPTGAPQWKGYFGD-UHFFFAOYSA-N 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- DQDYFFXIISPDLN-RBUKOAKNSA-N methyl 3-(cyanomethyl)-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-carboxylate Chemical compound C(#N)CC1(CN(C1)C(=O)OC)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1 DQDYFFXIISPDLN-RBUKOAKNSA-N 0.000 claims 1
- KSSGLLPOBYMBQL-UHFFFAOYSA-N methyl 3-(cyanomethyl)-3-[4-[[(2-phenylcyclopropyl)amino]methyl]piperidin-1-yl]azetidine-1-carboxylate Chemical compound COC(=O)N1CC(CC#N)(C1)N1CCC(CNC2CC2c2ccccc2)CC1 KSSGLLPOBYMBQL-UHFFFAOYSA-N 0.000 claims 1
- YGYJDIMVBSOMLI-VQTJNVASSA-N methyl 3-[2-(dimethylamino)-2-oxoethyl]-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-carboxylate Chemical compound CN(C(CC1(CN(C1)C(=O)OC)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)=O)C YGYJDIMVBSOMLI-VQTJNVASSA-N 0.000 claims 1
- XTENMDFQBUVJMC-RBUKOAKNSA-N methyl 3-[2-(methylamino)-2-oxoethyl]-3-[4-[[(1R,2S)-2-phenylcyclopropyl]amino]piperidin-1-yl]azetidine-1-carboxylate Chemical compound CNC(CC1(CN(C1)C(=O)OC)N1CCC(CC1)N[C@H]1[C@@H](C1)C1=CC=CC=C1)=O XTENMDFQBUVJMC-RBUKOAKNSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939458P | 2014-02-13 | 2014-02-13 | |
| US61/939,458 | 2014-02-13 | ||
| US201462061258P | 2014-10-08 | 2014-10-08 | |
| US62/061,258 | 2014-10-08 | ||
| PCT/US2015/015635 WO2015123424A1 (en) | 2014-02-13 | 2015-02-12 | Cyclopropylamines as lsd1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186168A Division JP6781815B2 (ja) | 2014-02-13 | 2019-10-09 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510555A JP2017510555A (ja) | 2017-04-13 |
| JP2017510555A5 true JP2017510555A5 (enExample) | 2018-03-29 |
| JP6602779B2 JP6602779B2 (ja) | 2019-11-06 |
Family
ID=52595463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016551815A Active JP6602779B2 (ja) | 2014-02-13 | 2015-02-12 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| JP2019186168A Active JP6781815B2 (ja) | 2014-02-13 | 2019-10-09 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| JP2020174661A Pending JP2021011496A (ja) | 2014-02-13 | 2020-10-16 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186168A Active JP6781815B2 (ja) | 2014-02-13 | 2019-10-09 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| JP2020174661A Pending JP2021011496A (ja) | 2014-02-13 | 2020-10-16 | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
Country Status (35)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為ｌｓｄ１抑制劑之環丙胺 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| WO2015123408A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| WO2016198649A1 (en) | 2015-06-12 | 2016-12-15 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| KR102720551B1 (ko) * | 2015-12-29 | 2024-10-21 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
| AU2017233898B2 (en) | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| CN107200706A (zh) * | 2016-03-16 | 2017-09-26 | 中国科学院上海药物研究所 | 一类氟取代的环丙胺类化合物及其制备方法、药物组合物和用途 |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| CN107459476B (zh) * | 2016-06-03 | 2022-06-24 | 中国科学院上海药物研究所 | 反吲哚啉环丙胺类化合物及其制备方法、药物组合物和用途 |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| CN110914265B (zh) | 2017-05-15 | 2022-12-23 | 密歇根大学董事会 | 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物 |
| MY204406A (en) | 2017-08-03 | 2024-08-27 | Oryzon Genomics Sa | Methods of treating behavior alterations |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| CN112119080B (zh) | 2018-05-15 | 2023-07-11 | 密歇根大学董事会 | 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN120837494A (zh) | 2019-03-20 | 2025-10-28 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| BR112021016064A2 (pt) | 2019-03-20 | 2021-10-05 | Oryzon Genomics, S.A. | Métodos de tratamento do transtorno de personalidade borderline |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| AU2023385514A1 (en) | 2022-11-24 | 2025-07-10 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| CN117164465B (zh) * | 2023-09-04 | 2025-07-01 | 郑州大学 | 一种苯基环丙胺类化合物及其制备方法和应用 |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (316)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7013068A (enExample) | 1969-09-17 | 1971-03-19 | ||
| US4537889A (en) | 1982-12-27 | 1985-08-27 | Eli Lilly And Company | Inotropic agents |
| US4614810A (en) | 1984-09-24 | 1986-09-30 | Pennwalt Corporation | 4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof |
| US4625040A (en) | 1984-09-24 | 1986-11-25 | Pennwalt Corporation | N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives |
| FR2607813B1 (fr) | 1986-12-05 | 1989-03-31 | Montpellier I Universite | Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique |
| JPH032778Y2 (enExample) | 1986-12-15 | 1991-01-24 | ||
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| JP2844351B2 (ja) | 1989-07-13 | 1999-01-06 | 株式会社科薬 | 安定なポリミキシン系抗生物質水性溶液 |
| IL96432A0 (en) | 1989-11-30 | 1991-08-16 | Schering Ag | Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives |
| FR2662163A1 (fr) | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
| JPH07507796A (ja) | 1992-06-17 | 1995-08-31 | ファルマシア・アンド・アップジョン・カンパニー | 抗−アテローム性動脈硬化剤および抗−高コレステロール血症剤として有用なピリジノ−，ピロリジノ−，およびアゼピノ−置換オキシム類 |
| JP2923139B2 (ja) | 1992-10-05 | 1999-07-26 | 三井化学株式会社 | 製 剤 |
| DE4327027A1 (de) | 1993-02-15 | 1994-08-18 | Bayer Ag | Imidazoazine |
| FR2711993B1 (fr) | 1993-11-05 | 1995-12-01 | Rhone Poulenc Rorer Sa | Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation. |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| KR20010031983A (ko) | 1997-11-11 | 2001-04-16 | 우에노 도시오 | 축합 피라진 화합물 |
| JP2000319277A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| JP2000319278A (ja) | 1999-05-11 | 2000-11-21 | Ono Pharmaceut Co Ltd | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 |
| JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
| JP4041624B2 (ja) | 1999-07-21 | 2008-01-30 | 三井化学株式会社 | 有機電界発光素子 |
| JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
| ATE450865T1 (de) | 1999-09-28 | 2009-12-15 | Panacea Biotec Ltd | Zusammensetzungen mit kontrollierter freigabe enthaltend nimesulid |
| SE9903611D0 (sv) | 1999-10-06 | 1999-10-06 | Astra Ab | Novel compounds III |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| JP4409680B2 (ja) | 1999-10-18 | 2010-02-03 | 株式会社ヤクルト本社 | 三環性縮合イミダゾール誘導体 |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| CA2407573C (en) | 2000-04-27 | 2011-09-13 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives |
| PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
| AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| WO2002006286A2 (en) | 2000-07-14 | 2002-01-24 | Bristol-Myers Squibb Pharma Company | IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| DE10050663A1 (de) | 2000-10-13 | 2002-04-18 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| DE60115282T2 (de) | 2000-11-10 | 2006-08-10 | Merck Sharp & Dohme Ltd., Hoddesdon | Imidazotriazin-derivate als liganden für gaba-rezeptoren |
| EP1343785A2 (de) | 2000-12-13 | 2003-09-17 | Basf Aktiengesellschaft | Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| WO2002072549A1 (en) | 2001-03-12 | 2002-09-19 | Millennium Pharmaceuticals, Inc. | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AU2003214873A1 (en) | 2002-01-18 | 2003-09-02 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| EP1576150A4 (en) | 2002-10-16 | 2006-05-03 | Univ Texas | METHOD AND COMPOSITIONS TO SAVE THE EFFECTIVENESS OF BIOLOGICALLY ACTIVE INGREDIENTS |
| CN1747949A (zh) | 2002-12-20 | 2006-03-15 | 法马西亚公司 | 无环吡唑化合物 |
| WO2004072081A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| ATE455547T1 (de) | 2003-04-11 | 2010-02-15 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen |
| EP1622616B1 (en) | 2003-04-24 | 2011-06-15 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| SE0301653D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| AR045697A1 (es) | 2003-07-14 | 2005-11-09 | Arena Pharm Inc | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7705052B2 (en) | 2003-09-12 | 2010-04-27 | Merck Serono Sa | Sulfonamide derivatives for the treatment of diabetes |
| JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| BRPI0415185A (pt) | 2003-10-10 | 2006-11-28 | Pfizer Prod Inc | 2h-[1,2,4]triazol[4,3-a]pirazinas substituìdas como inibidores da gsk-3 |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| WO2005044793A2 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
| JPWO2005063241A1 (ja) | 2003-12-26 | 2007-07-19 | 小野薬品工業株式会社 | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤 |
| JPWO2005077948A1 (ja) | 2004-02-16 | 2008-01-10 | 第一製薬株式会社 | 抗真菌作用複素環化合物 |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| BRPI0510319A (pt) * | 2004-04-26 | 2007-10-16 | Pfizer | inibidores da enzima integrase de hiv |
| JP5154924B2 (ja) | 2004-05-11 | 2013-02-27 | エガレット エイ／エス | ジェランガムを含む膨張可能な投与形態 |
| TW200612918A (en) | 2004-07-29 | 2006-05-01 | Threshold Pharmaceuticals Inc | Lonidamine analogs |
| BRPI0514391A (pt) | 2004-08-18 | 2008-06-10 | Pharmacia & Upjohn Co Llc | compostos de triazolopiridina para o tratamento de inflamação |
| EP1799671A4 (en) | 2004-09-02 | 2009-06-10 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| JP2008515874A (ja) | 2004-10-07 | 2008-05-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌薬 |
| US20090042820A1 (en) | 2004-11-22 | 2009-02-12 | Threshold Pharmaceuticals, Inc. | Tubulin Binding Anti Cancer Agents And Prodrugs Thereof |
| AU2005311451A1 (en) | 2004-12-01 | 2006-06-08 | Merck Serono Sa | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
| US20070293456A9 (en) | 2004-12-30 | 2007-12-20 | Anthony Hayford | Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
| US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| GEP20094727B (en) | 2005-02-22 | 2009-07-10 | Pfizer | Oxyindole derivatives as 5ht4 receptor agonists |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| CA2606288A1 (en) | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| DE602005023544D1 (de) | 2005-06-09 | 2010-10-21 | Oncalis Ag | Angiogeneseinhibitoren |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
| ES2349476T3 (es) | 2005-09-09 | 2011-01-03 | Schering Corporation | Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina. |
| KR20080074963A (ko) | 2005-11-10 | 2008-08-13 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 이미다조피라진 |
| MX2008006888A (es) | 2005-11-28 | 2008-09-30 | Marinus Pharmaceuticals | Formulas y metodos para la manufactura y uso de la ganaxolona. |
| JP4864982B2 (ja) | 2005-12-27 | 2012-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体 |
| WO2007074491A1 (en) | 2005-12-28 | 2007-07-05 | Universita Degli Studi Di Siena | HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS |
| PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| AU2007233709A1 (en) | 2006-03-31 | 2007-10-11 | Novartis Ag | Organic compounds |
| US7557104B2 (en) | 2006-06-06 | 2009-07-07 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| CA2655857C (en) | 2006-06-22 | 2014-12-02 | Mallinckrodt Inc. | Pyrazine derivatives with extended conjugation and uses thereof |
| DK2029554T3 (da) | 2006-06-22 | 2014-06-10 | Medibeacon Llc | Pyrazinderivater og anvendelser heraf til nyreovervågning |
| KR20090031544A (ko) | 2006-06-29 | 2009-03-26 | 쉐링 코포레이션 | 치환된 비사이클릭 및 트리사이클릭 트롬빈 수용체 길항제 |
| WO2008005423A1 (en) | 2006-07-03 | 2008-01-10 | Cambrex Charles City, Inc. | Improved method of making sufentanil |
| WO2008005908A2 (en) | 2006-07-07 | 2008-01-10 | Forest Laboratories Holdings Limited | Pyridoimidazole derivatives |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| BRPI0713187A2 (pt) | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| WO2008027812A2 (en) | 2006-08-28 | 2008-03-06 | Forest Laboratories Holdings Limited | Imidazopyridine and imidazopyrimidine derivatives |
| DE102006041292A1 (de) | 2006-09-01 | 2008-03-06 | Henkel Kgaa | Wasserstoffperoxid-Aktivierung mit N-Heterocyclen |
| WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
| ES2377821T3 (es) | 2006-10-11 | 2012-04-02 | Amgen Inc. | Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos. |
| CN101646419A (zh) | 2006-11-08 | 2010-02-10 | 诺瓦瓦克斯股份有限公司 | 制备多相药物组合物的固体剂型的方法 |
| WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
| CA2669991C (en) | 2006-11-22 | 2016-01-26 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| JP2010511018A (ja) | 2006-12-01 | 2010-04-08 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物 |
| US20100316712A1 (en) | 2006-12-22 | 2010-12-16 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
| US7803810B2 (en) | 2007-03-09 | 2010-09-28 | Probiodrug Ag | Inhibitors |
| DE102007012645A1 (de) | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| EP1972628A1 (en) | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines and aza-analog derivatives thereof as CNS active compounds |
| WO2008125111A1 (en) | 2007-04-16 | 2008-10-23 | Leo Pharma A/S | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
| EP2474549A1 (en) | 2007-04-17 | 2012-07-11 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| WO2008141249A1 (en) | 2007-05-10 | 2008-11-20 | Acadia Pharmaceuticals Inc. | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2168579B1 (en) | 2007-05-21 | 2017-10-11 | Toray Industries, Inc. | Oral preparation comprising specific organic acid, and method for improvement in dissolution property and chemical stability of oral preparation |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| CN101790526A (zh) | 2007-06-08 | 2010-07-28 | 雅培制药有限公司 | 用作激酶抑制剂的5-杂芳基取代的吲唑化合物 |
| WO2008156614A2 (en) | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
| US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| AU2008277628B2 (en) | 2007-07-18 | 2012-03-15 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| RU2010106878A (ru) | 2007-07-31 | 2011-09-10 | Шеринг Корпорейшн (US) | Комбинация антимитотического агента и ингибитора аврора киназы как средство для лечения рака |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| TW200922569A (en) | 2007-08-10 | 2009-06-01 | Genelabs Tech Inc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| US20090047336A1 (en) | 2007-08-17 | 2009-02-19 | Hong Kong Baptist University | novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation |
| FR2920090A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier. |
| FR2920091A1 (fr) | 2007-08-24 | 2009-02-27 | Oreal | Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier. |
| KR20090022616A (ko) | 2007-08-31 | 2009-03-04 | 한올제약주식회사 | 베실산클로피도그렐 함유 경구투여용 약제 |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| MX2010003927A (es) | 2007-10-11 | 2010-04-30 | Astrazeneca Ab | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. |
| CA2925175A1 (en) | 2007-10-12 | 2009-04-16 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| CA2704125A1 (en) | 2007-12-19 | 2009-07-09 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| KR100988233B1 (ko) | 2007-12-26 | 2010-10-18 | 한미홀딩스 주식회사 | 클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제 |
| ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
| US8507501B2 (en) | 2008-03-13 | 2013-08-13 | The Brigham And Women's Hospital, Inc. | Inhibitors of the BMP signaling pathway |
| WO2009114870A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| JPWO2009128520A1 (ja) | 2008-04-18 | 2011-08-04 | 塩野義製薬株式会社 | Ｐｉ３ｋ阻害活性を有する複素環化合物 |
| DE102008023801A1 (de) | 2008-05-15 | 2009-11-19 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine |
| US8349210B2 (en) | 2008-06-27 | 2013-01-08 | Transitions Optical, Inc. | Mesogenic stabilizers |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
| JP2010070503A (ja) | 2008-09-19 | 2010-04-02 | Daiichi Sankyo Co Ltd | 抗真菌作用２−アミノトリアゾロピリジン誘導体 |
| US20120021519A1 (en) | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| ES2403633T3 (es) | 2008-12-04 | 2013-05-20 | Proximagen Limited | Compuestos de imidazopiridina |
| US8450321B2 (en) | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| CA2749933A1 (en) | 2009-02-04 | 2010-08-12 | Supernus Pharmaceuticals, Inc. | Formulations of desvenlafaxine |
| CA2750517A1 (en) | 2009-02-04 | 2010-08-12 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TR200900878A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar |
| TR200900879A2 (tr) | 2009-02-05 | 2010-08-23 | Bi̇lgi̇ç Mahmut | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler |
| ES2435804T3 (es) | 2009-02-13 | 2013-12-23 | Bayer Intellectual Property Gmbh | Pirimidinas condensadas como inhibidores de Akt |
| KR20100101054A (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
| WO2010108059A1 (en) | 2009-03-20 | 2010-09-23 | Incyte Corporation | Substituted pyrimidine derivatives as antagonists of the histamine h4 receptor |
| CA2755132C (en) | 2009-03-31 | 2018-02-13 | Kissei Pharmaceutical Co., Ltd. | Indolizine derivative and use thereof for medical purposes |
| WO2010119264A1 (en) | 2009-04-16 | 2010-10-21 | Centro Nacional De Investigaciones Oncólogicas (Cnio) | Imidazopyrazines for use as kinase inhibitors |
| TWI461426B (zh) | 2009-05-27 | 2014-11-21 | Merck Sharp & Dohme | （二氫）咪唑並異〔５，１－ａ〕喹啉類 |
| EP2440563A1 (en) | 2009-06-10 | 2012-04-18 | Sunovion Pharmaceuticals Inc. | Histamine h3 inverse agonists and antagonists and methods of use thereof |
| WO2010151711A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
| US8546376B2 (en) | 2009-09-18 | 2013-10-01 | Almac Discovery Limited | Pharmaceutical compounds |
| KR101736218B1 (ko) | 2009-09-25 | 2017-05-16 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| US8614315B2 (en) | 2009-12-25 | 2013-12-24 | Mahmut Bilgic | Cefdinir and cefixime formulations and uses thereof |
| CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
| WO2011097607A1 (en) | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
| TW201200518A (en) | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
| RU2576662C2 (ru) | 2010-03-18 | 2016-03-10 | Энститю Пастер Корея | Противоинфекционные соединения |
| EP2547680B1 (en) | 2010-03-18 | 2015-08-05 | Bayer Intellectual Property GmbH | Imidazopyrazines |
| HRP20170712T1 (hr) | 2010-04-02 | 2017-07-28 | Ogeda Sa | Novi spojevi selektivnih antagonista nk-3 receptora, farmaceutski pripravak i postupci za uporabu kod poremećaja uzrokovanih nk-3 receptorima |
| ES2607081T3 (es) | 2010-04-19 | 2017-03-29 | Oryzon Genomics, S.A. | Inhibidores de desmetilasa específica de lisina-1 y su uso |
| EA022459B1 (ru) | 2010-04-20 | 2016-01-29 | Университа' Дельи Студи Ди Рома "Ла Сапиенца" | Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2 |
| AU2011246067A1 (en) | 2010-04-28 | 2012-09-27 | Daiichi Sankyo Company, Limited | [5,6] heterocyclic compound |
| MA34300B1 (fr) | 2010-05-13 | 2013-06-01 | Amgen Inc | Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10 |
| WO2011141713A1 (en) | 2010-05-13 | 2011-11-17 | Centro Nacional De Investigaciones Oncologicas (Cnio) | New bicyclic compounds as pi3-k and mtor inhibitors |
| CN102247321A (zh) | 2010-05-20 | 2011-11-23 | 上海亚盛医药科技有限公司 | 一种阿朴棉子酚酮自乳化药物传递系统及其制备方法 |
| EP2575808A1 (en) | 2010-05-28 | 2013-04-10 | Mahmut Bilgic | Combination of antihypertensive agents |
| CN102295642B (zh) | 2010-06-25 | 2016-04-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途 |
| ES2529119T3 (es) | 2010-07-02 | 2015-02-17 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| CA2804845A1 (en) | 2010-07-12 | 2012-01-19 | Stuart Ince | Substituted imidazo[1,2-a]pyrimidines and -pyridines |
| WO2012009475A1 (en) | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| CN101987082B (zh) | 2010-07-16 | 2013-04-03 | 钟术光 | 固体制剂及其制备方法 |
| CN101987081B (zh) | 2010-07-16 | 2012-08-08 | 钟术光 | 一种控释制剂 |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| LT2598482T (lt) * | 2010-07-29 | 2018-07-10 | Oryzon Genomics, S.A. | Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas |
| US9527805B2 (en) | 2010-09-10 | 2016-12-27 | Robert A. Casero | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| CN102397552B (zh) | 2010-09-10 | 2016-06-08 | 广州自远生物科技有限公司 | 一种含喹诺酮类的药物复合制剂及其制备方法和应用 |
| CN103221412B (zh) | 2010-09-29 | 2015-08-19 | 橘生药品工业株式会社 | (氮杂)中氮茚衍生物及其药物用途 |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| US20120108500A1 (en) | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
| US9023850B2 (en) | 2010-10-18 | 2015-05-05 | E I Du Pont De Nemours And Company | Nematocidal sulfonamides |
| EP2444084A1 (en) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Use of PI3K inibitors for the treatment of obesity |
| AR083502A1 (es) | 2010-10-21 | 2013-02-27 | Biomarin Pharm Inc | Sal tosilada de (8s,9r)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-dihidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona cristalina |
| WO2012052745A1 (en) | 2010-10-21 | 2012-04-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Combinations of pi3k inhibitors with a second anti -tumor agent |
| WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| US20140135319A1 (en) | 2010-12-17 | 2014-05-15 | Bayer Intellectual Property Gmbh | 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| EP2651950A1 (en) | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| UY33805A (es) | 2010-12-17 | 2012-07-31 | Boehringer Ingelheim Int | ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?. |
| CA2821817A1 (en) | 2010-12-17 | 2012-06-21 | Bayer Intellectual Property Gmbh | Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| JP5822944B2 (ja) | 2010-12-17 | 2015-11-25 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための２置換イミダゾピラジン |
| TWI617559B (zh) | 2010-12-22 | 2018-03-11 | 江蘇恆瑞醫藥股份有限公司 | ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物 |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| EP2665726A4 (en) | 2011-01-21 | 2014-09-03 | Gen Hospital Corp | COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES |
| US20140163041A1 (en) | 2011-02-08 | 2014-06-12 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| WO2012107498A1 (en) | 2011-02-08 | 2012-08-16 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN103857393B (zh) | 2011-03-25 | 2016-08-17 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 环丙基胺作为lsd1抑制剂 |
| WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| WO2012156531A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| WO2012156537A2 (en) | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| WO2012168882A1 (en) | 2011-06-07 | 2012-12-13 | SPAI Group Ltd. | Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| TW201311149A (zh) | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| UA114406C2 (uk) | 2011-08-09 | 2017-06-12 | Такеда Фармасьютікал Компані Лімітед | Похідні циклопропанаміну як інгібітори lsd1 |
| BR112014003382B1 (pt) | 2011-08-15 | 2022-03-15 | University Of Utah Research Foundation | Análogos de (e)-n-(1-feniletilideno) benzo-hidrazida substituída como inibidores de histona desmetilase e composições farmacêuticas compreendendo-os |
| WO2013033688A1 (en) | 2011-09-01 | 2013-03-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US9273343B2 (en) | 2011-09-02 | 2016-03-01 | Promega Corporation | Compounds and methods for assaying redox state of metabolically active cells and methods for measuring NAD(P)/NAD(P)H |
| EP2906562B1 (en) | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| CL2014000988A1 (es) | 2011-10-20 | 2014-11-03 | Oryzon Genomics Sa | Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia. |
| SI2776394T1 (sl) | 2011-10-20 | 2019-05-31 | Oryzon Genomics, S.A. | Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1 |
| EP3736265A1 (en) | 2011-10-20 | 2020-11-11 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| ITMI20111971A1 (it) | 2011-10-28 | 2013-04-29 | Mesogenics Srl | Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico |
| US9266881B2 (en) | 2011-11-14 | 2016-02-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone PDE10 inhibitors |
| CA2857964A1 (en) | 2011-12-05 | 2013-06-13 | Brandeis University | Treatment of amyloidosis by compounds that regulate retromer stabilization |
| ES2579981T3 (es) | 2012-03-07 | 2016-08-18 | Merck Patent Gmbh | Derivados de triazolopirazina |
| CN102587054B (zh) | 2012-03-13 | 2014-05-07 | 机械科学研究总院先进制造技术研究中心 | 缸盖自动锁紧装置及包括该装置的筒子纱染色机 |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| CN102579381B (zh) | 2012-03-30 | 2013-07-10 | 河南中帅医药科技发展有限公司 | 盐酸胍法辛缓释制剂及其制备方法 |
| CN103373996A (zh) | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
| ES2710491T3 (es) | 2012-06-28 | 2019-04-25 | Novartis Ag | Moduladores de la vía del complemento y sus usos |
| CN102772444A (zh) | 2012-07-06 | 2012-11-14 | 周明千 | 中药超微破壁口服片剂饮片的加工方法 |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| CN104768548B (zh) | 2012-09-28 | 2018-08-10 | 范德比尔特大学 | 作为选择性bmp抑制剂的稠合杂环化合物 |
| CA2887203A1 (en) | 2012-10-05 | 2014-04-10 | Rigel Pharmaceuticals, Inc. | 2,3-(hetero)aryl substituted pyridinyl compounds and their use as gdf-8 inhibitors |
| CN105051005B (zh) * | 2012-10-12 | 2017-06-13 | 武田药品工业株式会社 | 环丙胺化合物及其用途 |
| CA2890897A1 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt) |
| US9388123B2 (en) | 2012-11-28 | 2016-07-12 | Kyoto University | LSD1-selective inhibitor having lysine structure |
| WO2014085613A1 (en) | 2012-11-30 | 2014-06-05 | Mccord Darlene E | Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
| US9707275B2 (en) | 2012-12-19 | 2017-07-18 | Wockhardt Limited | Stable aqueous composition comprising human insulin or an analogue or derivative thereof |
| CN103054869A (zh) | 2013-01-18 | 2013-04-24 | 郑州大学 | 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用 |
| CN103933036B (zh) | 2013-01-23 | 2017-10-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途 |
| CA2901577A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| WO2014164867A1 (en) | 2013-03-11 | 2014-10-09 | Imago Biosciences | Kdm1a inhibitors for the treatment of disease |
| AU2014231768A1 (en) | 2013-03-13 | 2015-09-24 | Australian Nuclear Science And Technology Organisation | Transgenic non-human organisms with non-functional TSPO genes |
| US20140343118A1 (en) | 2013-03-14 | 2014-11-20 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| JP2016517434A (ja) | 2013-03-14 | 2016-06-16 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| WO2014194280A2 (en) | 2013-05-30 | 2014-12-04 | The Board of Regents of the Nevada System of Higher Education on behalf of the University of | Novel suicidal lsd1 inhibitors targeting sox2-expressing cancer cells |
| CN105555784B (zh) | 2013-06-19 | 2019-03-15 | 犹他大学研究基金会 | 作为组蛋白去甲基化酶抑制剂的被取代的(e)-n’-(1-苯亚乙基)苯甲酰肼类似物 |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9186391B2 (en) | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| WO2015031564A2 (en) | 2013-08-30 | 2015-03-05 | University Of Utah | Substituted-1h-benzo[d]imidazole series compounds as lysine-specfic demethylase 1 (lsd1) inhibitors |
| US9770514B2 (en) | 2013-09-03 | 2017-09-26 | ExxPharma Therapeutics LLC | Tamper-resistant pharmaceutical dosage forms |
| HUE035877T2 (en) | 2013-09-13 | 2018-05-28 | Bayer Pharma AG | Pharmaceutical preparations containing Refametinib |
| KR101568724B1 (ko) | 2013-11-13 | 2015-11-12 | 서울대학교산학협력단 | 신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도 |
| WO2015089192A1 (en) | 2013-12-11 | 2015-06-18 | Quanticel Pharmaceuticals, Inc. | Inhibitors of lysine specific demethylase-1 |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為ｌｓｄ１抑制劑之環丙胺 |
| WO2015123408A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN103893163B (zh) | 2014-03-28 | 2016-02-03 | 中国药科大学 | 2-([1，1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用 |
| KR102379518B1 (ko) | 2014-04-02 | 2022-03-25 | 브리스톨-마이어스 스큅 컴퍼니 | 비아릴 키나제 억제제 |
| EP2929884A1 (en) | 2014-04-11 | 2015-10-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and h2-receptor antagonists |
| WO2015155281A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
| CN106459024B (zh) | 2014-04-11 | 2019-11-05 | 武田药品工业株式会社 | 环丙胺化合物及其用途 |
| CN103961340B (zh) | 2014-04-30 | 2019-06-25 | 南通中国科学院海洋研究所海洋科学与技术研究发展中心 | 一类lsd1抑制剂及其应用 |
| MX375102B (es) | 2014-05-30 | 2025-03-06 | Ieo St Europeo Di Oncologia S R L | Compuestos de ciclopropilamina como inhibidores de histona demetilasa |
| CN104119280B (zh) | 2014-06-27 | 2016-03-16 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| CN104173313B (zh) | 2014-08-25 | 2017-05-17 | 杭州朱养心药业有限公司 | 利伐沙班片剂药物组合物 |
| JP6653116B2 (ja) | 2014-08-27 | 2020-02-26 | 日本ケミファ株式会社 | オルメサルタンのプロドラッグ製剤 |
| BR112017006829B1 (pt) | 2014-10-08 | 2023-01-31 | F. Hoffmann-La Roche Ag | Derivados de espirodiamina como inibidores de aldosterona sintase |
| MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| US10399933B2 (en) | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
| WO2016156597A1 (en) | 2015-04-03 | 2016-10-06 | Mutabilis | Heterocyclic compounds and their use in preventing or treating bacterial infections |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| CN105232488B (zh) | 2015-10-15 | 2021-05-04 | 上海凌凯医药科技有限公司 | 一种含有利伐沙班的固体药物组合物 |
| KR102720551B1 (ko) | 2015-12-29 | 2024-10-21 | 미라티 테라퓨틱스, 인크. | Lsd1 억제제 |
| JPWO2017130933A1 (ja) | 2016-01-25 | 2018-11-29 | 国立大学法人 熊本大学 | 神経変性疾患治療剤 |
| PE20190377A1 (es) | 2016-04-22 | 2019-03-08 | Incyte Corp | Formulaciones de un inhibidor de lsd 1 |
| US20200054643A1 (en) | 2017-01-18 | 2020-02-20 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| UA125592C2 (uk) | 2017-03-16 | 2022-04-27 | Джянгсу Хенгруй Медісін Ко., Лтд. | ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ |
| JOP20200342A1 (ar) | 2018-07-05 | 2020-12-30 | Incyte Corp | مشتقات بيرازين مدمجة كمثبطات a2a/a2b |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
-
2015
- 2015-02-12 TW TW104104830A patent/TWI664164B/zh active
- 2015-02-12 CA CA2939081A patent/CA2939081C/en active Active
- 2015-02-12 DK DK15707007.9T patent/DK3105226T3/da active
- 2015-02-12 RS RS20191440A patent/RS59534B1/sr unknown
- 2015-02-12 ES ES15707007T patent/ES2750956T3/es active Active
- 2015-02-12 MX MX2016010390A patent/MX373103B/es active IP Right Grant
- 2015-02-12 HR HRP20192033TT patent/HRP20192033T1/hr unknown
- 2015-02-12 MY MYPI2016001463A patent/MY196877A/en unknown
- 2015-02-12 JP JP2016551815A patent/JP6602779B2/ja active Active
- 2015-02-12 UA UAA201609399A patent/UA122389C2/uk unknown
- 2015-02-12 US US14/620,884 patent/US9493450B2/en active Active
- 2015-02-12 LT LT15707007T patent/LT3105226T/lt unknown
- 2015-02-12 TW TW108112023A patent/TWI720451B/zh active
- 2015-02-12 EP EP15707007.9A patent/EP3105226B1/en active Active
- 2015-02-12 EP EP19190056.2A patent/EP3626714A1/en not_active Withdrawn
- 2015-02-12 SI SI201530894T patent/SI3105226T1/sl unknown
- 2015-02-12 KR KR1020167025066A patent/KR102352408B1/ko active Active
- 2015-02-12 AU AU2015217119A patent/AU2015217119C1/en active Active
- 2015-02-12 NZ NZ723203A patent/NZ723203A/en unknown
- 2015-02-12 PT PT157070079T patent/PT3105226T/pt unknown
- 2015-02-12 PL PL15707007T patent/PL3105226T3/pl unknown
- 2015-02-12 PE PE2016001467A patent/PE20161384A1/es unknown
- 2015-02-12 WO PCT/US2015/015635 patent/WO2015123424A1/en not_active Ceased
- 2015-02-12 BR BR112016018555-2A patent/BR112016018555B1/pt active IP Right Grant
- 2015-02-12 CR CR20200362A patent/CR20200362A/es unknown
- 2015-02-12 CR CR20160395A patent/CR20160395A/es unknown
- 2015-02-12 EA EA201691594A patent/EA201691594A1/ru unknown
- 2015-02-12 SG SG11201606333VA patent/SG11201606333VA/en unknown
- 2015-02-12 SG SG10201806846RA patent/SG10201806846RA/en unknown
- 2015-02-12 CN CN201580019205.7A patent/CN106488915B/zh active Active
- 2015-02-12 SM SM20190620T patent/SMT201900620T1/it unknown
- 2015-02-12 HU HUE15707007A patent/HUE045725T2/hu unknown
- 2015-02-12 ME MEP-2019-315A patent/ME03580B/me unknown
-
2016
- 2016-07-26 IL IL246950A patent/IL246950B/en active IP Right Grant
- 2016-08-04 PH PH12016501546A patent/PH12016501546A1/en unknown
- 2016-08-10 CL CL2016002021A patent/CL2016002021A1/es unknown
- 2016-08-10 MX MX2020003702A patent/MX2020003702A/es unknown
- 2016-08-17 ZA ZA2016/05715A patent/ZA201605715B/en unknown
- 2016-09-09 EC ECIEPI201673171A patent/ECSP16073171A/es unknown
- 2016-10-07 US US15/288,605 patent/US9994546B2/en active Active
-
2018
- 2018-05-04 US US15/970,954 patent/US10676457B2/en active Active
-
2019
- 2019-06-17 AU AU2019204244A patent/AU2019204244B2/en active Active
- 2019-10-09 JP JP2019186168A patent/JP6781815B2/ja active Active
- 2019-11-21 CY CY20191101225T patent/CY1122314T1/el unknown
-
2020
- 2020-05-01 US US16/864,304 patent/US11155532B2/en not_active Expired - Fee Related
- 2020-09-13 IL IL277299A patent/IL277299B/en unknown
- 2020-10-16 JP JP2020174661A patent/JP2021011496A/ja active Pending